Registration onsite and Lunch
Session Opening and Introduction
Breast Cancer Session
Dr. Omalkhair Aboalkhair
Dr. Aisha Alharbi
DR. Ibrahim Madkhali
Dr. Majid Aljahel
Dr. Faress Husseini
Sadal Refai
Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
Dr. Shereef Elsamany
Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer.
Dr. Esam Murshid
3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC).
Dr Metab Alfohaidi
Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC)
Dr. Abokhair Algahmi
EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting (San Antonio 2022) .
Dr. Taleb Bohlaiqa
Abstracts Discussion (Practice changing Abstracts)
Prof. Joseph Gligorov 🇫🇷
Q&A and Panel Discussion
Satellite symposium (menarini) Topic: ER+HER- Advanced Breast cancer unmet Needs & Novel Endocrine Therapies
ChairPerson : Dr. Essam Murshid
Speaker : Dr. Nuhad K. Ibrahim
Dr. Esam Murshid
Nuhad K. Ibrahim 🇺🇸
Satellite symposium (Lilly) Topic: Updates on CDK4/6 in the Management of EBC
Chair Person : Dr. Taleb Bohlaiaqh
Speaker : Andreas Markis (UK)
Dr. Taleb Bohlaiqa
Dr. Andreas Markis 🇬🇧
Satellite Symposium (Novartis) Topic: Updates in Early Breast Cancer Management
ChairPerson :Dr. Taleb Bohlaiaqh
Speaker :Dr. Essam Murshid
Dr. Taleb Bohlaiqa
Dr. Esam Murshid
Break
Lung Cancer Session
Dr. Marwan Alhajeili
Prof. Ahmed Baddeeb
Dr. Waleed Baja
Dr. Hatem Majoub
Dr. Muneera Al Hussaini
Dr. Bandar Almutairi
Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).
Dr. Mervat Mahrous
KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.
Dr. Ahmed A. Refae
The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer with KRAS G12C mutation (WJOG14821L).
Dr. Abdullah Al Twigri
Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.
Dr. Shadi AlKhayyat
SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC).
Dr. Ahmed AlWabari
Abstracts Discussion (Practice changing Abstracts)
Dr. Santiago Viteri 🇪🇸
Polling + Q&A
Dr. Mervat Mahrous
Satellite symposium(Pfizer) First line treatment of ALK+ mNSCLC
ChairPerson : Dr. Taleb Bohlaiaqh
Speaker : Dr. Mervat Mahrous
Dr. Taleb Bohlaiqa
Dr. Mervat Mahrous
Satellite symposium(BMS) Local experience with dual IO blockade in Frontline mNSCLC
ChairPerson : Dr. Abdullah Altwairgi
Speaker : Dr. Waleed Alselwi
Dr. Abdullah Al Twigri
Dr. Waleed Alselwi
Panel Discussion and Wrap up & Closing
Gala DINNER
GU Cancer Session
Dr. Abdullah AlSharm
Dr. Abdulaziz Al Hamad
Dr. Faisal Albadainah
Dr. Eman bukhari
Dr. Omar Altaib
Welcome Day2 Session Opening and Introduction
Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk
Dr. Nedal Bukhari
Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy.
DR. Amin ElTigani
Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial
Dr. Faisal Azam
Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426
Dr. Fahad Bin Shamsa
Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial.
Dr. Mubarak Almansour
Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design
Dr. Yasser Bahader
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.
Dr. Rula AlMofti
Abstract Discussion (Practice changing Abstracts)
DR. Guillermo de Velasco 🇪🇸
Q&A and Panel Discussion
Satellite symposium (Janssen) Topic: Updates on the management of mHSPC
ChairPerson : Dr. Essam Murshid
Speaker : Dr. Aisha Alharbi
Satellite symposium (BMS) Topic:Treating Gastric cancer today. Clinical practice in KSA
ChairPerson : Dr. Ashwaq Alolayan
Speaker : Dr. Kanan Alshammari
Prayer & LUNCH Break
GI cancer Session
Dr. Hoda Mokhtar
Dr. Mohamed Alfayaz
Dr. Hazem Alotabi
Dr. Waleed Alselwi
Dr. Ahmed Mostafa
Dr. Ghanim Almotiri
PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).
Dr. Fahad Almokbal
Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial.
Dr. Ahmed Alshehri
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial
Dr. Kanan Alshamari
Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study.
Dr. Safwan Bakhsh
Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study
Dr. Mohamed Algarni
Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial
NRG/RTOG 1112: Randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC).
Dr. Ashwaq Alolayan
Abstract Discussion (What is Practice changing one)
Dr. Gerlad Prager 🇦🇹
POLLS/Q&A
Dr. Mervat Mahrous
Panel Discussion and Wrap up & Closing
